prevenar 13
pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f - pneumococcal infections; immunization - vacciner - aktiv immunisering för förebyggande av invasiv sjukdom, pneumoni och akut otitis media orsakad av streptococcus pneumoniae hos spädbarn, barn och ungdomar från 6 veckor till 17 år. aktiv immunisering för förebyggande av invasiv sjukdom orsakad av streptococcus pneumoniae hos vuxna ≥18 år och äldre. se avsnitt 4. 4 och 5. 1 för information om skydd mot specifika pneumokockserotyper. användningen av prevenar 13 skall bestämmas på grundval av officiella rekommendationer som tar hänsyn till risken för invasiv sjukdom i olika åldersgrupper, underliggande sjukdomstillstånd liksom variationen av serotyp epidemiologi i olika geografiska områden.
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenter för dermatit, med undantag av kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
diazemuls novum 5 mg/ml injektionsvätska, emulsion
orifarm ab - diazepam - injektionsvätska, emulsion - 5 mg/ml - sojaolja, raffinerad hjälpämne; glycerol hjälpämne; diazepam 5 mg aktiv substans
furosemid accord 10 mg/ml injektions-/infusionsvätska, lösning
accord healthcare b.v. - furosemid - injektions-/infusionsvätska, lösning - 10 mg/ml - furosemid 10 mg aktiv substans
ramipril/hydrochlorothiazide krka 5 mg/25 mg tablett
krka d.d., novo mesto - hydroklortiazid; ramipril - tablett - 5 mg/25 mg - ramipril 5 mg aktiv substans; hydroklortiazid 25 mg aktiv substans
ramipril/hydrochlorothiazide krka 2,5 mg/12,5 mg tablett
krka d.d., novo mesto - hydroklortiazid; ramipril - tablett - 2,5 mg/12,5 mg - hydroklortiazid 12,5 mg aktiv substans; ramipril 2,5 mg aktiv substans
ramipril/hydroklortiazid ebb 2,5 mg/12,5 mg tablett
ebb medical ab - hydroklortiazid; ramipril - tablett - 2,5 mg/12,5 mg - ramipril 2,5 mg aktiv substans; hydroklortiazid 12,5 mg aktiv substans
stesolid novum 5 mg/ml injektionsvätska, emulsion
orifarm ab - diazepam - injektionsvätska, emulsion - 5 mg/ml - diazepam 5 mg aktiv substans; glycerol hjälpämne; sojaolja, raffinerad hjälpämne
mepsevii
ultragenyx germany gmbh - vestronidase alfa - mucopolysaccharidosis vii - enzymer - mepsevii är indicerat för behandling av icke-neurologiska manifestationer av mucopolysaccharidosis vii (mps vii, sly syndrom).
suxamethonium aguettant 10 mg/ml injektionsvätska, lösning i förfylld spruta
laboratoire aguettant - suxametoniumklorid (vattenfri) - injektionsvätska, lösning i förfylld spruta - 10 mg/ml - suxametoniumklorid (vattenfri) 10 mg aktiv substans